Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

PURPOSE In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-
line platinum-based chemotherapy are robust, but responses lack durability. CheckMate …

Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by
rapid growth and the early development of metastases. Patients typically respond to initial …

Immune-checkpoint inhibitors (ICIs) are approved in the first-line and third-line settings for
patients with extensive-stage or relapsed small-cell lung cancer (SCLC), respectively. In the …

Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more
than two decades without clinical progress, the addition of programmed cell death protein 1 …

Small-cell lung cancer (SCLC) encounters up 15% of all lung cancers, and is characterized
by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis …

Metastasis is a major cause of morbidity and mortality in cancer patients. However, the
molecular and cellular mechanisms underlying the ability of cancer cells to metastasize …

Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor
prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately …

Background Patients with relapsed small-cell lung cancer (SCLC) have few treatment
options and dismal survival. Phase I/II data show activity of nivolumab in previously treated …